| Followers | 12 |
| Posts | 1963 |
| Boards Moderated | 0 |
| Alias Born | 04/16/2024 |
Monday, January 20, 2025 4:56:10 PM
Its relevant for people that are new to the board. Always look at how they started.
cliffnotes. Keep in mind the company is based in Jerusalem.
- The transaction represents an implied pro forma equity value of approximately $1 billion and is expected to provide up to $367 million in gross proceeds, including up to $275 million of cash held in the trust account of Healthcare Capital Corp. (Nasdaq: HCCC) and a $92 million PIPE.
- Citigroup is acting as financial advisor to Alpha Tau. Citigroup, Piper Sandler, and Cantor Fitzgerald are acting as joint placement agents on the PIPE. Cantor Fitzgerald is acting as a capital markets advisor to HCC. Value Base M&A Ltd. is also acting as financial advisor on the transaction.
Latham & Watkins LLP and Meitar | Law Offices are acting as legal advisors to Alpha Tau. Ellenoff Grossman & Schole LLP and FBC & Co. are acting as legal advisors to HCC. Winston & Strawn LLP is acting as legal advisor to the placement agents.
cliffnotes. Keep in mind the company is based in Jerusalem.
- The transaction represents an implied pro forma equity value of approximately $1 billion and is expected to provide up to $367 million in gross proceeds, including up to $275 million of cash held in the trust account of Healthcare Capital Corp. (Nasdaq: HCCC) and a $92 million PIPE.
- Citigroup is acting as financial advisor to Alpha Tau. Citigroup, Piper Sandler, and Cantor Fitzgerald are acting as joint placement agents on the PIPE. Cantor Fitzgerald is acting as a capital markets advisor to HCC. Value Base M&A Ltd. is also acting as financial advisor on the transaction.
Latham & Watkins LLP and Meitar | Law Offices are acting as legal advisors to Alpha Tau. Ellenoff Grossman & Schole LLP and FBC & Co. are acting as legal advisors to HCC. Winston & Strawn LLP is acting as legal advisor to the placement agents.
Recent DRTS News
- Alpha Tau Announces First-Ever Oral Presentation of Alpha DaRT® Pancreatic Cancer Data at Digestive Disease Week (DDW) 2026 • GlobeNewswire Inc. • 03/31/2026 01:15:00 PM
- Alpha Tau to Present at Sidoti March Virtual Small Cap Conference • GlobeNewswire Inc. • 03/16/2026 02:02:00 PM
- Alpha Tau Announces Full Year 2025 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 03/09/2026 08:02:00 PM
- Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead • GlobeNewswire Inc. • 01/29/2026 02:00:00 PM
- DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event • ACCESS Newswire • 01/23/2026 07:50:00 PM
- Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study • GlobeNewswire Inc. • 01/06/2026 02:00:00 PM
- Throwing Precision Darts: The Company Leading Next Evolution of Cancer Radiation • AllPennyStocks.com • 01/05/2026 05:38:00 PM
- Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC) • GlobeNewswire Inc. • 01/05/2026 02:00:00 PM
- Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference • GlobeNewswire Inc. • 12/18/2025 02:00:00 PM
- Sidoti Events, LLC's Year-End Virtual Investor Conference • ACCESS Newswire • 12/09/2025 05:48:00 PM
- Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University • GlobeNewswire Inc. • 12/09/2025 02:00:00 PM
- Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium • GlobeNewswire Inc. • 12/04/2025 02:00:00 PM
- Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer • GlobeNewswire Inc. • 12/02/2025 02:00:00 PM
- Alpha Tau to Participate in December Investor Conferences • GlobeNewswire Inc. • 12/01/2025 02:00:00 PM
- Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/20/2025 09:05:00 PM
- Alpha Tau to Participate at Jefferies Global Healthcare Conference in London • GlobeNewswire Inc. • 11/11/2025 01:30:00 PM
- Alpha Tau Announces Receipt of Radioactive Material License for its New Hampshire Manufacturing Facility, Advancing Towards Commercial Readiness • GlobeNewswire Inc. • 10/21/2025 12:30:00 PM
- Alpha Tau Successfully Treats First Patient in its U.S. Multi-Center Pancreatic Cancer Clinical Trial • GlobeNewswire Inc. • 09/02/2025 12:30:00 PM
- Alpha Tau to Participate in Five September Investor Conferences • GlobeNewswire Inc. • 08/27/2025 12:30:00 PM
- Alpha Tau Announces Second Quarter 2025 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 08/11/2025 08:02:00 PM
- Alpha Tau to Present at Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/28/2025 12:30:00 PM
- Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 05/19/2025 08:01:00 PM
- Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors • GlobeNewswire Inc. • 05/12/2025 08:01:00 PM
- Alpha Tau to Participate in May Investor Conferences • GlobeNewswire Inc. • 05/06/2025 12:30:00 PM
- Oramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical • PR Newswire (US) • 04/28/2025 01:00:00 PM
